The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Open accessAbstract
Purpose: We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) for patients with KRAS wild-type metastatic colorectal cancer. Patients and Methods: Start of subsequent-line (second or third) therapy was defined as use of an antitumor drug that was not part of the previous regimen. We evaluated choice, duration, and efficacy of subsequent therapy and determined the impact of subsequent-line treatment on outcome of patients in FIRE-3. Results: Of 592 patients in the intent-to-treat population, 414 (69.9%) received second-line and 256 (43.2%) received third-line therapy. In subsequent treatment lines, 47.1% of patients originally assigned to arm A received bevacizumab, and 52.2% originally assigned to arm B received either cetuximab or panitumumab. Oxaliplatin was subsequently used in 55.9% (arm A) and 53.2% (arm B) of patients. Second-line therapy was administered for a median duration of 5.0 versus 3.2 months (P < .001) in study arm A versus B. Progression-free (6.5 v 4.7 months; hazard ratio, 0.68; 95% CI, 0.54 to 0.85; P < .001) and overall survival (16.3 v 13.2 months; hazard ratio, 0.70; 95% CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A compared with arm B. Conclusion: Our data suggest that the sequence of drug application might be more important than exposure to single agents. In patients with RAS wild-type tumors, first-line application of anti–epidermal growth factor receptor–directed therapy may represent a favorable condition for promoting effective subsequent therapy including antiangiogenic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC).”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citationSchmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,534
Self-citationVan Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 955
Self-citation
Research works printed but not linked: 3
- Koopman M, 2014, J Clin Oncol, 32
- Hegewisch-Becker S, 2014, Ann Oncol, 25
- Viloria-Petit A, 2001, Cancer Res, 61, 5090
Cited by
Sorted by citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 337
Self-citationWatanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
S3-Leitlinie – Kolorektales Karzinom
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 247
Self-citationHeinemann, V., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173
Self-citationStintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 138
Self-citationRivera, F., Karthaus, M., Hecht, J. R., Sevilla, I., Forget, F., Fasola, G., Canon, J.-L. R., Guan, X., Demonty, G., & Schwartzberg, L. S. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2800-1 · Cited by 137
Rumpold, H. F., Niedersüß‐Beke, D., Heiler, C., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07656-w · Cited by 122
Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.028 · Cited by 91
Self-citationBennouna, J., Hiret, S., Bertaut, A., Bouché, O., Deplanque, G., Borel, C., François, É., Conroy, T., Ghiringhelli, F., Guetz, G. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4465 · Cited by 88
Ciombor, K. K., & Bekaii‐Saab, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0203 · Cited by 74
Baraniskin, A., Buchberger, B., Pox, C. P., Graeven, U., Holch, J. W., Schmiegel, W., & Heinemann, V. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.009 · Cited by 75
Self-citationHeinemann, V., Rivera, F., O’Neil, B. H., Stintzing, S., Koukakis, R., Terwey, J.-H., & Douillard, J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.019 · Cited by 59
Self-citationMultiple treatment lines and prognosis in metastatic colorectal cancer patients
Carlomagno, C., Stefano, A. D., Rosanova, M., Falco, S. D., Attademo, L., Fiore, G., & Placido, S. D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9748-7 · Cited by 59
Tabernero, J. M., Argilés, G., Sobrero, A. F., Borg, C., Ohtsu, A., Mayer, R. J., Vidot, L., Vera, S. R. M., & Cutsem, E. V. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000752 · Cited by 58
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Aderka, D., Stintzing, S., & Heinemann, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30172-x · Cited by 55
Self-citationTargeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 50
Self-citationHuang, Z., Rui, X., Chen, Y., Chen, Y., Chen, R., Liang, Y., Wang, Y., Yao, W., Xu, X., & Huang, Z. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02618-z · Cited by 49
Laurent‐Puig, P., Grisoni, M.-L., Heinemann, V., Liebaert, F., Neureiter, D., Jung, A., Montestruc, F., Gaston‐Mathé, Y., Thiébaut, R., & Stintzing, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1324 · Cited by 48
Self-citationKovaleva, V., Geißler, A.-L., Lutz, L., Fritsch, R., Makowiec, F., Wiesemann, S. D., Hopt, U. T., Passlick, B., Werner, M., & Laßmann, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0549-8 · Cited by 46
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives
Holch, J. W., Stintzing, S., & Heinemann, V. (2016) · Visceral Medicine · doi:10.1159/000446052 · Cited by 45
Self-citationLiu, N., Wu, C., Jia, R., Cai, G., Wang, Y., Zhou, L., Ji, Q., Sui, H. X., Zeng, P., Xiao, H., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00478 · Cited by 43
Role of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. F. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 42
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 47
Avallone, A., Piccirillo, M. C., Nasti, G., Rosati, G., Carlomagno, C., Gennaro, E. D., Romano, C., Tatangelo, F., Granata, V., Cassata, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18475 · Cited by 37
Immunotherapy as an Option for Cancer Treatment
Rusch, T., Bayry, J., Werner, J., Shevchenko, I., & Bazhin, A. V. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0491-5 · Cited by 35
Zaniboni, A., & Formica, V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3032-8 · Cited by 32
Modest, D. P., Rivera, F., Bachet, J., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G., & Douillard, J.-Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32110 · Cited by 32
Self-citationRen, L., Zhu, D., Benson, A. B., Nordlinger, B., Koehne, C.-H., Delaney, C. P., Kerr, D. J., Lenz, H., Fan, J., Wang, J., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.02.019 · Cited by 33
Grassadonia, A., Marino, P. D., Ficorella, C., Cortellini, A., Cannita, K., Parisi, A., Gamucci, T., Zoratto, F., Vici, P., Barba, M., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34550 · Cited by 31
Cascinu, S., Rosati, G., Nasti, G., Lonardi, S., Zaniboni, A., Marchetti, P., Leone, F., Bilancia, D., Iaffaioli, R. V., Zagonel, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.029 · Cited by 30
Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 29
Osawa, H. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1145 · Cited by 26
Helden, E. J. V., van Oordt, C. W. M. D. H., Heymans, M. W., Ket, J. C. F., van den Oord, R., & Verheul, H. M. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9668-y · Cited by 27
Pinto, C., Fabio, F. D., Rosati, G., Lolli, I. R., Ruggeri, E. M., Ciuffreda, L., Ferrari, D., Re, G. L., Rosti, G., Tralongo, P., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.888 · Cited by 25
Cao, D., Xu, H., Xu, X., & Ge, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19022 · Cited by 25
Efficacy‐effectiveness gaps in oncology: Looking beyond survival
Wilson, B. E., Hanna, T. P., & Booth, C. M. (2023) · Cancer · doi:10.1002/cncr.35075 · Cited by 25
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
Modest, D. P., Heinemann, V., Folprecht, G., Denecke, T., Pratschke, J., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08219-w · Cited by 23
Self-citationNew developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 23
Poston, G. J., Adam, R. A., Xu, J., Byrne, B., Esser, R., Malik, H., Wasan, H. S., & Xu, J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.07.021 · Cited by 21
Parisi, A., Cortellini, A., Cannita, K., Venditti, O., Camarda, F., Calegari, M. A., Salvatore, L., Tortora, G., Rossini, D., Germani, M. M., et al. (2020) · Cancers · doi:10.3390/cancers12051259 · Cited by 21
Cheng, Y., DU, F. C., Fang, F., DUAN, Z. J., LEI, W., & SHI, K. G. (2020) · Neoplasma · doi:10.4149/neo_2020_191125n1212 · Cited by 21
O’Neil, B. H., & Venook, A. P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8495 · Cited by 22
Ciracì, P., Germani, M. M., Pietrantonio, F., Manca, P., Lonardi, S., Busico, A., Bergamo, F., Burgio, V., Mannavola, F., Donato, S. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.002 · Cited by 24
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., Kahl, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30592 · Cited by 20
Self-citationChebib, R., Verlingue, L., Cozic, N., Faron, M., Burtin, P. C., Boige, V., Hollebecque, A., & Malka, D. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.07.004 · Cited by 21
Chen, D., Gu, K., & Wang, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s196170 · Cited by 21
Pinto, C., Orlandi, A., Normanno, N., Maiello, E., Calegari, M. A., Antonuzzo, L., Bordonaro, R., Zampino, M. G., Pini, S., Bergamo, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01021 · Cited by 19
Peeters, M., Forget, F., Karthaus, M., Valladares‐Ayerbes, M., Zaniboni, A., Demonty, G., Guan, X., & Rivera, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000297 · Cited by 19
Wang, Y., Zhao, M., Zhao, H., Cheng, S., Bai, R., & Song, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195364 · Cited by 19
Harty, G. T., Jarrett, J., & Jofre‐Bonet, M. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-018-0395-5 · Cited by 18
Holch, J. W., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.001 · Cited by 18
Self-citationHolch, J. W., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Lerchenmuller, C. A., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31114 · Cited by 16
Self-citationCann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16
Bai, L., Wang, F., Li, Z.-Z., Ren, C., Zhang, D., Zhao, Q., Lu, Y., Wang, D., Ju, H., Qiu, M., et al. (2016) · Medicine · doi:10.1097/md.0000000000004531 · Cited by 15
Rumpold, H. F., Kirchweger, P., Niedersüß‐Beke, D., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1837945 · Cited by 15
Li, W., Hu, T., Zhou, L., Feng, Y., Wang, Y., & Jin, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2493-9 · Cited by 15
Economic evaluation study (CHEER-compliant)
Zhou, J., Zhao, R., Wen, F., Zhang, P., Tang, R., Chen, H., Zhang, J., & Li, Q. (2016) · Medicine · doi:10.1097/md.0000000000003762 · Cited by 14
Tao, B., Yi, C., Ma, Y., Li, Y., Zhang, B., Geng, Y., Chen, Z., Ma, X., & Chen, J. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10591-7 · Cited by 13
Taniguchi, H., Baba, Y., Sagiya, Y., Gotou, M., Nakamura, K., Sawada, H., Yamanaka, K., Sakakibara, Y., Mori, I., Hikichi, Y., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.006 · Cited by 13
Hsu, H., Liu, Y., Wang, C., Chou, W., Hsu, Y., Chiang, J., Lin, Y., & Yang, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2235 · Cited by 13
Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
Marques, R. P., Godinho, A. R., Heudtlass, P., Pais, H. L., Quintela, A., & Martins, A. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03167-0 · Cited by 12
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial
Avallone, A., & Budillon, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1512 · Cited by 10
Tsai, H., Lin, C., Sung, Y.-C., Chen, S., Chen, L., Jiang, J., & Wang, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02366-z · Cited by 9
Kassouf, E., Tabchi, S., & Tehfe, M. A. (2016) · BioDrugs · doi:10.1007/s40259-016-0166-5 · Cited by 9
Froelich, M. F., Petersen, E. L., Heinemann, V., Nörenberg, D., Hesse, N., Gesenhues, A. B., Modest, D. P., Sommer, W. H., Hofmann, F. O., Stintzing, S., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.005 · Cited by 9
Self-citationXu, Z., Peng, X., Kong, Y., Cui, Y., Li, Y., & Guo, Y. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100455 · Cited by 9
Büchler, T., Chloupková, R., Poprach, A., Fiala, O., Kišš, I., Kopečková, K., Dušek, L., Veškrňová, V., Slavicek, L., Kohoutek, M., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s183093 · Cited by 9
Fucà, G., Raimondi, A., Prisciandaro, M., Lonardi, S., Cremolini, C., Ratti, M., Clavarezza, M., Murialdo, R., Bianchi, A. S., Smiroldo, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab012 · Cited by 9
Zhang, C., Liu, L., Lv, Y., Li, J., Cao, C., Lu, J., Wang, S., Du, B., & Yang, X. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2147512 · Cited by 9
Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101636 · Cited by 9
Modest, D. P., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.030 · Cited by 8
Self-citationBurge, M., Semira, C., Lee, B., Lee, M., Kosmider, S., Wong, R., Shapiro, J. D., Ma, B. B. Y., Dean, A. P., Zimet, A. S., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.009 · Cited by 8
Liu, S., Jiang, C., Yang, L., Huang, J., Peng, R., Wang, X., He, W., Bai, L., Zhou, Y., Zhang, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69230-5 · Cited by 9
Stahler, A., Heinemann, V., Schuster, V., Heinrich, K., Kurreck, A., Gießen-Jung, C., von Weikersthal, L. F., Kaiser, F., Decker, T. W., Held, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.017 · Cited by 8
Self-citationPrice, T. J., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D. G., Punt, C. J. A., Arnold, D., Karapetis, C. S., Tebbutt, N. C., Pavlakis, N., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170594 · Cited by 9
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Nagayasu, K., Naito, S., Sato, T., Kishine, K., Abe, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6960 · Cited by 8
Abrahão, A. B. K., Karim, S., Colwell, B., Berry, S. R., & Biagi, J. J. (2017) · Current Oncology · doi:10.3747/co.24.3757 · Cited by 7
Wang, J., Luo, L., Wang, D., Guo, B., Li, J., Zhu, Y., & Tang, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26312 · Cited by 8
First-line treatment in metastatic colorectal cancer: Important or crucial?
Malka, D., Rotolo, F., & Boige, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.001 · Cited by 6
Galvano, A., Incorvaia, L., Badalamenti, G., Rizzo, S., Guarini, A. A., Cusenza, S., Castellana, L., Barraco, N., Calò, V., Cutaia, S., et al. (2019) · Cancers · doi:10.3390/cancers11081189 · Cited by 6
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Li, D., Wang, F., Xu, S., Li, K., Meng, X., Huang, Y., Ma, N., Qiao, L., Kuang, G., Chen, J., et al. (2021) · Journal of Cancer · doi:10.7150/jca.60014 · Cited by 5
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
Stahler, A., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., von Weikersthal, L. F., Caca, K., Goekkurt, E., Ballhausen, A., Sommerhäuser, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103004 · Cited by 4
Self-citationSzemitko, M., Golubinska-Szemitko, E., Sieńko, J., Falkowski, A., & Wiernicki, I. (2023) · Cancers · doi:10.3390/cancers15020541 · Cited by 4
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift
Robinson, H. R., & Lieu, C. H. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1088 · Cited by 4
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy
Ishioka, C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103062 · Cited by 4
Zhou, Y., Zhao, X., Lu, N., Cao, P., Leng, W.-B., Zhu, Q., Gou, H., Zhang, J., Li, X., & Qiu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111887 · Cited by 3
Urban, H., Maurer, G. D., Luger, A., Lorenz, N. I., Sauer, B., Stroh, C., Trojan, J., Mittelbronn, M. G. A., Steinbach, J., Harter, P. N., et al. (2020) · Cancers · doi:10.3390/cancers12103050 · Cited by 3
Wu, C., Hsu, C., Hsieh, M., Wang, J., Chang, M., Yang, C., & Su, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215166 · Cited by 3
Nasti, G., & Ottaiano, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9086 · Cited by 3
Nardo, P. D., Basile, D., Siciliano, A., Pelizzari, G., Corvaja, C., Buriolla, S., Ongaro, E., Grazia, D. M., Garattini, S. K., Foltran, L., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.013 · Cited by 3
Physical insights guided rational design of anti-EGFR antibody to reverse the acquired resistance
Zhang, M., Fu, Y., Xie, T., Yang, Z., Zhang, D., & Zhou, R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141304 · Cited by 2
Wang, Z., Wang, H., Ma, B., Gao, P., Song, Y., Xu, Q., Zhang, C., & Hu, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111240 · Cited by 2
Metadata
- Authors
- Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Held, S., Möhler, M., Jung, A., Kirchner, T., & Heinemann, V.
- Affiliations
- German Cancer Research Center (DE)
- Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3718-3726
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110977364
- Cited by
- 121
- References
- 20
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 14 · 2022: 5 · 2021: 8 · 2020: 16 · 2019: 10 · 2018: 12 · 2017: 23 · 2016: 19 · 2015: 2
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type tumors, FIRE-3 trial, FOLFIRI, cetuximab, bevacizumab, panitumumab, second-line therapy, third-line therapy, anti-EGFR therapy, anti-angiogenic therapy, oxaliplatin, treatment sequencing, progression-free survival, overall survival
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Proto-Oncogene Proteins, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, ras Proteins, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
